GILD
Gilead Sciences · Health Care
4.3%
typical move (median |reaction| of last 8)
2026-10-29 post · likely
next expected · estimated from pattern
12
scored events
Last eight reactions
2024-11-06 → 2026-08-04
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-08-04 | post | -2.6% | 2.6% | +2.7% | +14.1% |
| 2026-05-07 | post | -2.1% | 2.1% | -1.5% | -2.6% |
| 2026-02-10 | post | +5.8% | 5.8% | -1.9% | -3.1% |
| 2025-10-30 | post | +1.2% | 1.2% | +0.9% | +4.1% |
| 2025-08-07 | post | +8.2% | 8.2% | -1.9% | -4.7% |
| 2025-04-24 | post | -2.8% | 2.8% | -2.4% | -1.1% |
| 2025-02-11 | post | +7.5% | 7.5% | +5.3% | +18.2% |
| 2024-11-06 | post | +6.8% | 6.8% | -5.5% | -7.9% |
Source filings
2026-08-04 · 8-K press release
GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 10% Year-Over-Year to $7.6 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.8 billion
2026-05-07 · 8-K press release
GILEAD SCIENCES ANNOUNCES FIRST QUARTER FINANCIAL RESULTS Product Sales Excluding Veklury Increased 8% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.4 billion Foster
2026-02-10 · 8-K press release
GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $28.0 billion for Full Year 2025 Biktarvy Sales Increased 7
2025-10-30 · 8-K press release
GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $7.1 billion Biktarvy Sales Increased 6% Year-Over-Year to $3.7 billion Fo
2025-08-07 · 8-K press release
GILEAD SCIENCES ANNOUNCES SECOND QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.9 billion Biktarvy Sales Increased 9% Year-Over-Year to $3.5 billion F
2025-04-24 · 8-K press release
GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2025 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 4% Year-Over-Year to $6.3 billion Biktarvy Sales Increased 7% Year-Over-Year to $3.1 billion Fo
2025-02-11 · 8-K press release
GILEAD SCIENCES ANNOUNCES FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 8% Year-Over-Year to $26.8 billion for Full Year 2024 Biktarvy Sales Increased 1
2024-11-06 · 8-K press release
GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 7% Year-Over-Year to $6.8 billion Biktarvy Sales Increased 13% Year-Over-Year to $3.5 billion O